
Opinion|Videos|November 24, 2025
The Underlying Causes of GCA: Environmental and Genetic Factors
Advertisement
Episodes in this series

This video covers the following questions:
- What do we currently understand about the underlying causes (i.e., pathogenesis and the inflammatory pathways) of GCA?
- What role do genetics or environmental exposures appear to play in developing this disease?
- How might the presence of comorbidities (such as hypertension, osteoporosis, cataracts, etc.) impact the screening and diagnosis of GCA? What diagnostic pearls can you share on screening patients for GCA with comorbidities?
Advertisement
Related to this article

Ankeet Bhatt, MD, MBA, ScM, explains how prediction markets could threaten clinical trial integrity by undermining participant retention and trust.

Diana Isaacs, PharmD, and Natalie Bellini, DNP, review OPTIMAL-DIABETES, SYNCHRONIZE-CVOT, and ATTAIN-OSA data from AHA 2026.

Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss tubeless Mobi's FDA clearance, CVS Caremark's CGM formulary shift, and a transmitter-free implant.

Aficamten's label now includes MAPLE-HCM data, in which aficamten monotherapy improved peak VO2 by 2.3 mL/kg/min more than metoprolol at 24 weeks.

Dexmedetomidine sublingual film is the first FDA-approved at-home option for acute agitation, based on the phase 3 SERENITY at-home trial.

Hiddo Heerspink, PharmD, PhD, joins Brendon Neuen, MBBS, PhD, and Shikha Wadhwani, MD, MS, to unpack finerenone’s FIND-CKD data in FSGS.

Lesley Inker, MD, MS, joins Brendon Neuen, MBBS, PhD, to unpack GFR slope and hierarchical composite endpoints in glomerular disease trials.
Advertisement
Advertisement
Trending on HCPLive
1
ABCs in Dermatology: Rethinking Corticosteroid Stewardship in Chronic Hand Eczema
2
FDA Updates Aficamten Label With MAPLE-HCM Data in Obstructive HCM
3
Early Dupilumab in Pediatric EoE Tied to Lower Incident Asthma
4
Upadacitinib Response Within Days in Crohn’s Disease, With Raja Atreya, MD
5

